Top Telehealth Companies in NYC, NY (61)

Profitability: Profitability is highlighted as first achieved in 2023 and sustained thereafter, with the company also describing itself as cash‑flow positive. These signals point to durable unit economics and financial health.

Strong Revenue Growth: Revenue is described as growing quickly over multiple years with momentum expected to continue, while efficiency benchmarks such as the Rule of 40 have been surpassed. Together, these indicators suggest efficient, scalable growth.

Strategic Partnerships: New integrations and channels—such as embedded real‑time booking on Yelp, Healthgrades, and Google’s Gemini, along with payer partnerships—are expanding distribution and reinforcing growth. These collaborations broaden patient access points and help providers secure bookings.

Strong Revenue Growth: Available information indicates revenue reaccelerated in 2024 to an annualized level around $600M, propelled overwhelmingly by the GLP‑1‑centered Ro Body program. This momentum emerged in late 2023 and continued through 2024.

Strategic Partnerships: Pharma integrations expanded with Eli Lilly offering Zepbound vials via Ro in December 2024 and Novo Nordisk naming Ro as a telehealth partner for the nationwide Wegovy pill launch in 2026. These arrangements broaden access to on‑label GLP‑1s and fortify supply channels.

Market Expansion: Manufacturer affordability and subscription initiatives in 2025–2026 explicitly included partners like Ro, widening access points and supporting patient acquisition and retention in obesity care. The addition of the Wegovy pill via telehealth increased the addressable market beyond injectables.

Investor Backing & Capital Strength: Back-to-back Series D ($118M, Feb 2026) and Series E ($100M, May 2026) at step-up valuations to roughly $1.35B and $2.74B point to ample runway and strong investor confidence. Participation from firms such as Index Ventures, Kleiner Perkins, Sequoia, Thrive, Founders Fund, Redpoint, and Kaiser Permanente Ventures underscores capital strength.

Strong Revenue Growth: Company disclosures cite approximately $200M in gross annual recurring revenue with revenue more than doubling for five consecutive years, including over 130% year-over-year growth noted in early 2026. Nearly 800 customers and millions of covered members are also cited as evidence of expanding commercial scale.

Strategic Partnerships: New collaborations in 2026 with Priority Health and Atlantic Health expand distribution into health plan and regional employer channels. Priority Health separately confirmed the partnership and product launch.

Investor Backing & Capital Strength: Funding is described as a $15.5M Series A in October 2025 led by Costanoa Ventures with participation from Town Hall Ventures and Khosla Ventures, following an earlier 2024 seed. The round is explicitly framed to scale access, hiring, product, and market expansion.

Market Expansion: Go‑to‑market activity is described as expanding beyond New York into states like New Jersey and Ohio with active deployments and continued outreach into 2025–2026. Company materials and public profiles reference multi‑state operations and ongoing hiring to broaden footprint.

Strategic Partnerships: School‑district collaborations are highlighted (e.g., Millville Public Schools) alongside positioning as a school‑centered therapy platform aimed at K‑12 administrators and counselors. The model integrates school‑based referrals with insurer coverage, indicating partnership‑driven growth.

Investor Backing & Capital Strength: Recent financing includes a $50 million Series B in April 2025, described as oversubscribed and led by Key1 Capital. This injection is framed as fuel for hiring, product expansion, and go‑to‑market activity.

Strategic Partnerships: Channel integrations such as Homethrive and availability within the PrismHR ecosystem, along with selections by platforms like Vensure and a collaboration with TriNet, expand distribution reach. These moves are presented as widening access to employers and SMBs through established ecosystems.

Innovation-Driven Growth: Product velocity includes launches like Healthee Connect in 2025 and new AI capabilities such as AI-powered Claims Analytics and “Zoe for HR” in 2026. This cadence signals continued investment beyond core benefits Q&A toward analytics and broader platform functionality.

Investor Backing & Capital Strength: New capital of a $72M Series C on May 29, 2025 (bringing total funding to roughly $162M) is confirmed by the company and independent outlets, signaling capacity to scale. Feedback suggests this funding underpins continued product and market build-out.

Market Expansion: Expansion beyond the U.S., including a UK launch in December 2025, shows growing geographic reach. Third-party confirmation from Zurich UK highlights at-scale deployment to over 3 million Life Protection customers in a new market.

Strategic Partnerships: Large-scale distribution agreements with blue-chip insurers such as Zurich UK and Transamerica materially increase potential reach. These relationships embed the platform within established carrier channels across multiple regions.

Strong Revenue Growth: Repeated Inc. 5000 recognition through 2025–2026 points to sustained multi‑year top‑line expansion. This ongoing external acknowledgement aligns with signals of continued growth momentum.

Market Expansion: The acquisition of Joshin in 2025 extends the platform into integrated neurodiversity and disability support, broadening the company’s reach beyond its historical software footprint. Partnerships and integrations with adjacent platforms further widen distribution and cross‑sell opportunities.

Innovation-Driven Growth: Multiple 2026 launches—Session Note AI, an AI Dashboard for ABA operations, and BillAI—illustrate a rapid product cadence aimed at deepening adoption and upsell. This pace of releases underscores continued investment in AI and workflow automation.

Market Expansion: Geographic reach is presented as Medicare-covered virtual therapy available across all 50 states, with therapist-by-state listings that signal recent build-out. Statements about operating across many states and serving hundreds to thousands of patients reinforce an expanding footprint.

Strong Hiring & Retention: Active recruiting is visible via an Ashby-powered careers site with roles like a Founding Engineer and multiple remote therapist postings, alongside additional listings on job boards. LinkedIn shows a 51–200 employee range with 140+ listed profiles, consistent with team expansion.

Strategic Partnerships: A collaboration with Advanced Nursing & Home Care (January 2025) extends access through senior-care channels. In-network positioning with Medicare supports referral-driven growth among older adults.

Investor Backing & Capital Strength: Large late-stage financing, including a $100M Series C in May 2026 that brought total funding to about $215M, signals ample runway and external confidence. Coverage of a valuation step-up around $1.75B and participation from prominent firms reinforces balance-sheet strength.

Strategic Partnerships: In‑network status with major insurers and expanding relationships with health plans, employers, and health systems are emphasized across recent materials. Access to 160M–200M+ covered lives and significant health‑system referrals indicate robust commercialization channels.

Strong Revenue Growth: Recognition on the 2026 Inc. 5000 and statements of year‑over‑year acceleration point to rapid top‑line expansion. Directional revenue signals align with sharp increases in patients served and provider capacity.

Strong Market Position & Advantage: Evidence indicates USPI leads the ambulatory surgery center sector by footprint and market standing, consistently referenced as the largest national platform. Industry and company descriptions highlight broad scale, procedure volume, and leadership within a consolidating yet fragmented market.

Strong Revenue Growth: Descriptions point to steady year-over-year increases in ambulatory segment revenue and earnings through 2024–2025, with raised outlooks signaling sustained momentum. Same-facility growth and higher revenue per case underscore a durable top-line trajectory.

Market Expansion: Evidence shows rapid network growth via acquisitions and de novo centers across many states and specialties. Partnerships and joint ventures with physician groups and health systems further extend geographic reach and service breadth.

Investor Backing & Capital Strength: Capital access is described as exceptional, with over $1B in total funding and a valuation rising to $5.3B across successive rounds backed by top‑tier and strategic investors. This depth of financing signals ample runway for R&D and go‑to‑market scale.

Strong Revenue Growth: Revenue momentum is highlighted by contracted ARR of $117M in early 2025 and estimates that actual ARR crossed $100M by mid‑2025, alongside a 4x increase over 18 months. These points indicate rapid monetization of enterprise deployments.

Market Expansion: Enterprise adoption expanded from roughly 100–150 health systems in early/mid‑2025 to more than 250–300 by mid‑2026, including large rollouts at Kaiser Permanente and other marquee systems. Scaling conversation volume from ~50M in 2025 to a projected 80M+ in 2026 underscores a widening footprint.